Muquith, Maishara
Espinoza, Magdalena
Elliott, Andrew
Xiu, Joanne
Seeber, Andreas
El-Deiry, Wafik http://orcid.org/0000-0002-9577-8266
Antonarakis, Emmanuel S.
Graff, Stephanie L.
Hall, Michael J.
Borghaei, Hossein http://orcid.org/0000-0002-2577-4454
Hoon, Dave S. B.
Liu, Stephen V.
Ma, Patrick C.
McKay, Rana R. http://orcid.org/0000-0002-0581-7963
Wise-Draper, Trisha
Marshall, John
Sledge, George W.
Spetzler, David
Zhu, Hao http://orcid.org/0000-0002-8417-9698
Hsiehchen, David http://orcid.org/0000-0001-9139-302X
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas
Article History
Received: 12 July 2023
Accepted: 28 February 2024
First Online: 25 March 2024
Competing interests
: A.E., J.X., G.W.S. and D.S. are employees of Caris Life Sciences. S.L.G. serves a paid consultant and advisor to Pfizer, Daiichi Sankyo, Eli Lilly, AstraZeneca, Genentech, SeaGen, Novartis and Menarini and has stock ownership in HCA Healthcare. E.S.A. serves as a paid consultant and advisor to Janssen, Astellas, Sanofi, Dendreon, Bayer, BMS, Amgen, Constellation, Blue Earth, Exact Sciences, Invitae, Curium, Pfizer, Merck, AstraZeneca, Clovis and Eli Lilly; has received research support (to his institution) from Janssen, J&J, Sanofi, BMS, Pfizer, AstraZeneca, Novartis, Curium, Constellation, Celgene, Merck, Bayer and Clovis; and is the co-inventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. The other authors declare no competing interests.